Freeline Therapeutics Holdings Stock Working Capital
| FRLNDelisted Stock | USD 4.31 0.28 6.10% |
Freeline Therapeutics Holdings fundamentals help investors to digest information that contributes to Freeline Therapeutics' financial success or failures. It also enables traders to predict the movement of Freeline Stock. The fundamental analysis module provides a way to measure Freeline Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Freeline Therapeutics stock.
Freeline |
Freeline Therapeutics Holdings Company Working Capital Analysis
Freeline Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Freeline Therapeutics Working Capital | 36.66 M |
Most of Freeline Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Freeline Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, Freeline Therapeutics Holdings has a Working Capital of 36.66 M. This is 91.39% lower than that of the Biotechnology sector and 93.19% lower than that of the Health Care industry. The working capital for all United States stocks is 97.52% higher than that of the company.
Freeline Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Freeline Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Freeline Therapeutics could also be used in its relative valuation, which is a method of valuing Freeline Therapeutics by comparing valuation metrics of similar companies.Freeline Therapeutics is currently under evaluation in working capital category among its peers.
Freeline Fundamentals
| Return On Equity | -1.01 | |||
| Return On Asset | -0.56 | |||
| Current Valuation | 2.78 M | |||
| Shares Outstanding | 4.36 M | |||
| Shares Owned By Insiders | 1.09 % | |||
| Shares Owned By Institutions | 45.88 % | |||
| Number Of Shares Shorted | 23.93 K | |||
| Price To Book | 0.94 X | |||
| Price To Sales | 45.40 X | |||
| Revenue | 622 K | |||
| EBITDA | (64.84 M) | |||
| Net Income | (49.93 M) | |||
| Cash And Equivalents | 90 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 5.92 M | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 3.68 X | |||
| Book Value Per Share | 6.89 X | |||
| Cash Flow From Operations | (64.24 M) | |||
| Short Ratio | 1.92 X | |||
| Earnings Per Share | (11.40) X | |||
| Target Price | 8.25 | |||
| Number Of Employees | 152 | |||
| Beta | 0.66 | |||
| Market Capitalization | 28.24 M | |||
| Total Asset | 86.64 M | |||
| Retained Earnings | (445.35 M) | |||
| Working Capital | 36.66 M | |||
| Z Score | -6.29 | |||
| Net Asset | 86.64 M |
About Freeline Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Freeline Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Freeline Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Freeline Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Freeline Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Freeline Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Freeline Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Freeline Stock
| 0.71 | MOGO | Mogo Inc | PairCorr |
| 0.63 | MCK | McKesson | PairCorr |
| 0.6 | PLTR | Palantir Technologies Aggressive Push | PairCorr |
| 0.54 | WMT | Walmart | PairCorr |
| 0.49 | UAL | United Airlines Holdings Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Freeline Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Freeline Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Freeline Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Freeline Therapeutics Holdings to buy it.
The correlation of Freeline Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Freeline Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Freeline Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Freeline Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Freeline Stock
If you are still planning to invest in Freeline Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Freeline Therapeutics' history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |